Bio-Oil 60ml
www.apotiktambakrejo.com - 23Tahun Melayani Pembelian Obat-Obatan Farmasi - Whatsapp 1 : 085102402995 / Whatsapp 2 : 08883005027 / New Pin BB : 56E94B90 / Harga di website tidak UPDATE mohon konfirmasi dahulu


#2 of 14 | prev product Prev - Next next product
printer email

product arrow ARTRODAR 50MG CAP

Price Rp 8.200 Beli

Harga Tersebut diatas Tidak Mengikat, Sewaktu-Waktu Dapat Berubah Tanpa Pemberitahuan Terlebih Dahulu


Each capsule of ARTRODAR contains diacerein 50 mg; Lactose monohydrate, Croscarmellose sodium, Polyvidone K30,' Colloidal silicon dioxide, Magnesium stearate.

Anti-osteoarthritis and anti-inflammatory drug in degenerative jointdisease (osteoarthritis and related diseases). Due to its specific mode of action, which does not involve the inhibition of prostaglandin synthesis, diacerein has been shown to have anti-osteoarthritis and cartilage stimulating properties in vitro and in animal models, together with anti-inflammatory properties. Diacerein has shown  disease-modifying properties in animal models of osteoarthritis. In clinical trials, ARTRODAR significantly improved osteoarthritis symptoms such as pain and joint dysfunction. The beneficial effects of ARTRODAR are observed after 2-4 weeks of treatment, with significant improvement appearing after about 4-6 weeks of treatment,  and are still present for about 2 months after treatment has stopped (carry-over effect). A combination therapy with an analgesic or a NSAID may be recommended during the first 2-4 weeks of treatment.

After oral administration, diacerein is hydrolysed before entering the systemic circulation and is absorbed, metabolised and excreted
as rhein and its conjugates. All the pharmacokinetics data that follow refer to this active principle.

After oral  administration  diacerein  undergoes  a first  hepatic passage and is totally deacetylated to rhein. After the intake of a
IIIIIIIII single dose of 100 mg, the peak plasma levels (Cmax) were 8-1 Ong/ml of free rhein. The values for Tmax were 1.8-2.0. hours after administration to fasting healthy volunteers. The simultaneous intake of a standard meal induces a delay in the absorption process and prolongs the Tmax together which results in a higher bioavailability (increase of about 25% in the AUC). Given this behaviour, it is advisable to take the drug with meals.

Nearly all the non-conjugated rhein (more than 99%) is bound to plasma proteins, mainly albumin, and is not displaced by the usual
drugs at their therapeutic concentrations. The mean distribution volume is steady state, Vss/F, was approximately 17.1 litres.

Diacerein is very rapidly metabolised (mainly pre-systematically) to rhein and this is conjugated to different extents in each species.

The elimination half-life of plasma (t1/2) is about 5-7 hours. Excretion is mainly renal as rhein and as conjugates of rhein (glucuronide and sulphate). Following oral administration of doses of 50-100 mg, about 50% of the total dose of diacerein is recovered in the urine as rhein, mainly (more than 90%) as the sulpho-and gluco-conjugated forms of rhein.

In lineraity studies using doses between 50 and 200 mg diacerein,the Cmax and AUC of free and total rhein were proportional to the
doses administered.

Pharmacokinetics in special groups of patents
In cirrhotic patients with mild to moderate hepatic insufficiency, no statistically significant changes were observed in any of the pharmacokinetic parameters of rhein as determined from plasma or urine concentrations in comparison to a reference group of healthy subjects of a similar age.
Consequently, it is not necessary to modify the diacerein dose in these patients (see-Posology and method of administration) On the other hand, a comparison between healthy subjects and patients with renal insufficiency shows that there is a highly significant increase in the AUC and terminal half-life (t1/2) with a simultaneous decline in renal clearance of rhein in subjects with severe renal   insufficiency   (creatinine   clearance less than 30 ml/min).Consequently diacerein is contraindicated in this type of patients In patients with moderate renal insufficiency, a 50% reduction in the daily dose is recommended (see Posology and method of administration and Contraindications). Finally, when elderly patients are compared to a control group of younger healthy volunteers, an increase in the AUC proportional to age and a prolongation of the terminal plasma half-life of free rhein are observed.However, these findings did not reach the necessary significance to require a modification of the dose in these patients.Therefore,   as   has  already  been   stated   in  the  dosage  and administration section, the dose for elderly patients is the same as that   for   younger   adults   (see   Posology   and   method   of administration).

Symptomatic relief in long-term treatment of osteoarthritis.

Diacerein should not be administered to patients with known hypersensitivity to the drug itself or to those with previous episodes of hypersensitivity to anthraquinone derivatives. Temporary treatment suspension must be considered in case of antibiotic therapy, which may affect intestinal flora and kinetics The benefit / risk ratio of administering ARTRODAR to patients with previous episodes of enterocolic disturbances, especially irritable colon, must be considered. Severe hepatic or renal insufficiency Use in children
Pregnancy and lactation Intestinal obstruction or pseudo-obstruction Inflammatory intestinal disease (ulcerative colitis, Crohn disease)

Accelerated intestinal transit is the most frequently reported side-effect (7%) associated with ARTRODAR treatment. The symptoms
may appear within the first few days of treatment. In most cases these symptoms resolve spontaneously with continuing treatment.
Diarrhoea and epigastric pain and disturbances were reported in 3-5% of the treated patients, with nausea and vomiting reported in
less than 1 % of the patients. A pigmentation of the recto-colic mucosa (melanosis coli) has been observed rarely (1-10% of the patients). The intake of ARTRODAR may sometimes result in a more intense yellow colouring of the urine. This is typical of the type of
compound and is,of no clinical significance. Effects on the skin and subcutaneous tissue Some cases of pruritus, eczema and cutaneous eruptions have been reported (1-10% of the patients).

Renal insufficiency modifies the pharmacokinetics of diacerein and therefore a  dose  reduction  is  recommended  in  such  cases
(creatinine clearance < 30ml/min) When diacerein is taken with food, there is an increase (about 24%) in its absorption; on the other hand, severe nutritional deficiencies decrease the bioavailability of diacerein. As the incidence of collateral effect, such as accelerated intestinal transit time, is directly proportional to the amount of unabsorbed diacerein, the intake of the product in a fasting state or after very small amounts of food could cause an increased incidence of collateral effects.

Pregnancy and lactation
Although animal studies did not reveal any toxic effects on fertility or foetal development, ARTRODAR should not be administered
during   pregnancy. In addition, ARTRODAR should not be prescribed to lactating women due to reports that small amounts of diacerein derivatives pass into the maternal milk. Effect on ability to drive and use machines No sedative effect, which may affect the ability to handle machines, is known for diacerein. ARTRODAR should not be prescribed to children below 15 years old as no clinical studies have been undertaken in this age-group. Laxatives should not be taken concomitantly with ARTRODAR.

The accidental or voluntary ingestion of high doses of diacerein could produce diarrhoea. No specific antidotes exist. If diarrhoea persists, please see your doctor. Emergency treatment consists of restoring the hydroelectrolytic balance if necessary.

Diacerein must not be administered at the same time as drugs that modify intestinal transit and/ or the quality of the intestinal content
(e.g. excess fibres or phytates). The concomitant administration of products containing aluminium hydroxide and/ or magnesium hydroxide should be avoided in order to maximise the bioavailability of diacerein. Treatment with diacerein may cause an increase in enterocolic events in patients undergoing antibiotic and/ or chemotherapy which could affect the intestinal flora.

The usual dosage regimen for ARTRODAR in one capsule taken orally twice a day with the main meals for prolonged periods (not
less than 6 months) However, as diacerein may cause acceleration intestinal transit time during the first 2 weeks of treatment, it is recommended that treatment be started with one capsule of ARTRODAR per day taken orally with evening meal for 4 weeks.
Once the patient has become accustomed to the medication, the dose should be increased to 2 capsules per day, taken orally with
meals. The doctor should decide the duration of treatment as a function of the outcome. However this should not be less than 6 months.
As with prolonged treatment with any other medication, a complete blood test, including liver enzymes, and urinalysis should be
conducted every 6 months. Due its late onset of action (after 2-4 weeks of treatment), diacerein may be associated with a non-steroidal anti-inflammatory drug or analgesic for the first 2-4 weeks' of treatment.

No clinical studies have been conducted in children. As the safety and efficacy of the product have not been established in this age
group, its use is not recommended {see-Contraindications) Elderly No change in the usual recommended d.ose is necessary in elderly
subjects (see-Pharmacokinetic properties).

Renal insufficiency
In subjects with moderate renal insufficiency, the daily dose should be decreased by 50% of the recommended dose for adults (see-
Pharmacokinetic properties) ARTRODAR  is  contraindicated  in  subjects with  severe  renal insufficiency (see-Contraindication)

Hepatic insufficiency
No significant deviations were observed in any of the pharmacokinetic parameters in cirrhotic patients with mild or moderate hepatic insufficiency and therefore no dose adjusment is required in these patients {see-Pharmacokinetic properties). However, the use of diacerein is contraindicated in patients with a severe deterioration of hepatic function {see-Contraindication) SHELF LIFE AND SPECIAL PRECAUTIONS FOR STORAGE Shelf lite If stored as indicated below, this medication can be used until the date stated on the packaging. The shelf life of the tablets is 3 years. Special precautions for storage Store in a dry place, protected from light and at room temperature (15°-25°C) in a well closed packaging.

Box, 3 Blisters @ 10 Capsules      Reg. No. DKI 0411100101A1

-_-^              Manufactured by:
jfofH            TRB Pharma S.A., Argentina
5^*\/              Under license from:
TRB Chemedica International S.A., Geneva, Switzerland
CnuDiujAD     Imported by: UMBIPHAR     PT. COMBIPHAR, Bandung, Indonesia